Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. Before joining Xconomy, he was the U.S. biotechnology reporter for Bloomberg News, based in San Francisco. There, he led coverage of major medical meetings and broke news about the industry’s top companies. His stories appeared in The New York Times, Los Angeles Times, Boston Globe, and International Herald Tribune. Before that, his passionate coverage of biotechnology won many awards for The Seattle Times.
While at the Times, Luke was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award, the Sigma Delta Chi prize from the Society of Professional Journalists, the Society of American Business Editors and Writers award, an honorable mention Gerald Loeb Award, and was nominated for the Pulitzer Prize in public service. He was named one of the nation's top biotech writers in 2010 by FierceBiotech.
Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison. In 2005-2006, he was a Knight Science Journalism Fellow at MIT. In his spare time, Luke enjoys distance running, mountaineering, and fantasy baseball. Having grown up in Wisconsin, he is, naturally, a lifelong fan of the Green Bay Packers and the Wisconsin Badgers.
-
Biotech pilgrims are gathering today for the biggest industry frenzy of the year, the JP Morgan Healthcare Conference. This confab in San Francisco’s Union Square is the singular place each... Read more »
-
South San Francisco-based Theravance said today that Astellas Pharma, its longtime partner in marketing a new antibiotic, has decided to walk away from its collaboration.
Theravance (NASDAQ: THRX) said Japan-based Astellas... Read more »
-
Pacific Biosciences is bringing in an industry pioneer, Michael Hunkapiller, as its new CEO after a disappointing first year on the market with its new breed of DNA sequencing instrument.
The... Read more »
-
Some people set a goal of losing weight in the new year, but if you’re Bob Langer and Omid Farokhzad, it’s apparently time to start another new biotech company.
The prolific biotech entrepreneurs... Read more »
-
A little more than 4 million children are born in the U.S. every year, and quite a few of those prospective parents are curious about potential genetic defects in their offspring. And so... Read more »
-
Seattle-based Mirador Biomedical has won FDA clearance to market its medical device for a new set of uses, which doctors have been asking about for months.
Mirador said today that its digital pressure... Read more »
-
[Update: 6:58 am PT] Dendreon greatly disappointed investors in 2011, but it ended up closing the year out on a stronger note than expected.
The Seattle-based biotech company (NASDAQ: DNDN)... Read more »
-
Another six months have gone by, so it must be time for another deal for Forma Therapeutics.
Sure enough, Watertown, MA-based Forma is announcing today it has struck a partnership to discover... Read more »
-
Isis Pharmaceuticals has found a new partner in Biogen Idec that’s betting a large amount of money on a new therapy for a rare spinal disorder in newborns.
Weston, MA-based Biogen Idec (NASDAQ: BIIB) said... Read more »
-
Alnylam Pharmaceuticals has been saying for a while that it needs hard data from clinical trials to prove its skeptics wrong, and today it’s coming out with an early hint of effectiveness... Read more »
-
Seattle-based Allozyne has made a small set of job cuts after it was unable to pull the trigger on its plan to go public late last year, Xconomy has learned.
Allozyne has let... Read more »
-
Seattle-based JeNu Biosciences has raised some new cash to go after the emerging market for ultrasound-based skin care devices.
The company has pulled in $1.5 million from Seattle’s Second Avenue Partners and... Read more »
-
[Updated] Aveo Pharmaceuticals is starting the New Year with news that it has passed the most important clinical trial in company history, although it appears to have barely eked... Read more »
-
It’s Editor’s Picks time at the end of the year, which is a sure sign that your local journalists are looking to stick something on the site you can read during a slow... Read more »
-
Seattle-based Allozyne wasn’t able to go public this year, so it has fallen back on Plan B, tapping its existing venture capital backers one more time in a bid to create... Read more »
-
Yesterday, we ran the first half of the Seattle life sciences year in review, which focused on biopharmaceutical companies and global health organizations. Today’s rundown will cover the medical device,... Read more »
-
Seattle-based Allozyne spent the last six months trying to go public by merging into the shell of what used to be an active, publicly traded biotech company.
But in the end, the... Read more »
-
This was a great year for Seattle biotech if you measure success through sheer number of acquisitions. But if you prefer to measure the health of an innovation community by the number... Read more »
-
Tuan Ha-Ngoc remembers feeling like he belonged in the bottom 10 percent in terms of intelligence at Genetics Institute when he was getting started in the 1980s.
Looking back, he says he... Read more »
-
Japan-based Takeda Pharmaceuticals, which has its cancer drug development operations in Cambridge, MA, said today it is acquiring San Diego-based Intellikine to get ahold of the startup’s portfolio of cancer drugs.
Takeda... Read more »
